BML Capital Management LLC Invests $2.73 Million in Design Therapeutics, Inc. (NASDAQ:DSGN)

BML Capital Management LLC bought a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) during the 4th quarter, Holdings Channel reports. The firm bought 1,029,478 shares of the company’s stock, valued at approximately $2,728,000. Design Therapeutics accounts for about 2.1% of BML Capital Management LLC’s investment portfolio, making the stock its 12th largest holding.

Several other large investors also recently made changes to their positions in DSGN. RTW Investments LP grew its holdings in shares of Design Therapeutics by 60.8% during the third quarter. RTW Investments LP now owns 2,512,986 shares of the company’s stock worth $5,931,000 after purchasing an additional 949,955 shares during the last quarter. Prescott Group Capital Management L.L.C. acquired a new position in shares of Design Therapeutics during the third quarter valued at $425,000. Strs Ohio acquired a new position in shares of Design Therapeutics during the third quarter valued at $171,000. Barclays PLC lifted its stake in shares of Design Therapeutics by 353.1% during the third quarter. Barclays PLC now owns 71,678 shares of the company’s stock valued at $170,000 after acquiring an additional 55,858 shares during the period. Finally, Jump Financial LLC lifted its stake in shares of Design Therapeutics by 284.7% during the third quarter. Jump Financial LLC now owns 46,700 shares of the company’s stock valued at $110,000 after acquiring an additional 34,561 shares during the period. Institutional investors own 56.64% of the company’s stock.

Wall Street Analyst Weigh In

DSGN has been the topic of several research reports. Wedbush reaffirmed a “neutral” rating and set a $5.00 price target on shares of Design Therapeutics in a research note on Wednesday, March 20th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price target on shares of Design Therapeutics in a research note on Wednesday, March 20th. Seven research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $5.50.

Design Therapeutics Trading Down 5.9 %

NASDAQ:DSGN opened at $3.66 on Wednesday. Design Therapeutics, Inc. has a 1-year low of $1.94 and a 1-year high of $8.47. The business’s 50-day moving average price is $3.23 and its two-hundred day moving average price is $2.65. The firm has a market capitalization of $206.75 million, a price-to-earnings ratio of -3.05 and a beta of 1.82.

Design Therapeutics (NASDAQ:DSGN) last released its earnings results on Tuesday, March 19th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.11. Sell-side analysts predict that Design Therapeutics, Inc. will post -1.25 earnings per share for the current year.

Insider Buying and Selling at Design Therapeutics

In related news, Director John P. Schmid bought 17,809 shares of the business’s stock in a transaction on Monday, March 25th. The shares were purchased at an average price of $3.74 per share, with a total value of $66,605.66. Following the completion of the purchase, the director now owns 26,965 shares of the company’s stock, valued at approximately $100,849.10. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. In other Design Therapeutics news, Director John P. Schmid purchased 9,156 shares of the company’s stock in a transaction dated Friday, March 22nd. The shares were bought at an average price of $3.62 per share, with a total value of $33,144.72. Following the completion of the transaction, the director now directly owns 9,156 shares in the company, valued at approximately $33,144.72. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John P. Schmid purchased 17,809 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were acquired at an average cost of $3.74 per share, for a total transaction of $66,605.66. Following the transaction, the director now owns 26,965 shares of the company’s stock, valued at $100,849.10. The disclosure for this purchase can be found here. Insiders own 25.70% of the company’s stock.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.